The concept of psoriasis as a systemic inflammation: Implications for disease management

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue SUPPL. 2, 2012, Pages 3-11

  Reich, K ^a  

^a DERMATOLOGIKUM HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADIPOCYTOKINE; BRIAKINUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ADIPOCYTE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; GENETIC PREDISPOSITION; HEART INFARCTION; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INSULIN RESISTANCE; LIFE EXPECTANCY; MEDIATOR RELEASE; MENTAL DISEASE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; STROKE; SYSTEMIC DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; METABOLIC SYNDROME X; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857603197     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04410.x     Document Type: Review

References (76)

1. Lebwohl M,. Psoriasis. Lancet 2003; 361: 1197-1204. (Pubitemid 36398393)
2. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M,. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151.
3. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-46.
4. Henseler T, Christophers E,. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
5. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835. (Pubitemid 44556851)
6. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M,. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
7. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S,. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123-127. (Pubitemid 43260727)
8. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741. (Pubitemid 44547793)
9. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230. (Pubitemid 38461682)
10. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I,. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636.
11. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499. (Pubitemid 350277763)
12. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 2011; Oct 21. [Epub ahead of print].
13. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-651. (Pubitemid 46232884)
14. Torti DC, Feldman SR,. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007; 57: 1059-1068.
15. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-1211. (Pubitemid 351543220)
16. Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009; 123: 1244-1252.
17. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159: 1092-1102.
18. Spah F,. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008; 159 (Suppl 2): 10-17.
19. Griffiths CEM, Barker JNWN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271. (Pubitemid 47069537)
20. Li Y, Begovich AB,. Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis. Semin Immunol 2009; 21: 318-327.
21. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM,. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-592.
22. Ahlehoff O, Gislason GH, Jorgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2011; Aug 25. [Epub ahead of print].
23. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775, e771-e776.
24. Farley E, Menter A,. Psoriasis: comorbidities and associations Giornale italiano di dermatologia e venereologia: organo ufficiale. Societa italiana di dermatologia e sifilografia 2011; 146: 9-15.
25. Reich K, Huffmeier U, Konig IR, et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007; 56: 2056-2064. (Pubitemid 47110405)
26. Muller-Ladner U, Alten R, Heiligenhaus A, et al. ["TRECID", TNFalpha related chronic inflammatory diseases-a new multiple diseases bridging concept]. Dtsch Med Wochenschr 2009; 134: 2132-2136.
27. Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M,. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989-1004.
28. Pereira MG, Brito L, Smith T,. Dyadic adjustment, family coping, body image, quality of life and psychological morbidity in patients with psoriasis and their partners. Int J Behav Med 2011; Jun 25. [Epub ahead of print].
29. Schneider G, Heuft G, Hockmann J,. Determinants of social anxiety and social avoidance in psoriasis outpatients. J Eur Acad Dermatol Venereol 2011; Oct 17. [Epub ahead of print].
30. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73. (Pubitemid 46934281)
31. Vasku V, Kankova K, Vasku A, et al. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch Dermatol Res 2002; 294: 127-130. (Pubitemid 34591574)
32. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY,. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009; 60: 225-230.
33. Sanchez FO, Linga Reddy MV, Mallbris L, Sakuraba K, Stahle M, Alarcon-Riquelme ME,. IFN-regulatory factor 5 gene variants interact with the class I MHC locus in the Swedish psoriasis population. J Invest Dermatol 2008; 128: 1704-1709. (Pubitemid 351847380)
34. Danik JS, Pare G, Chasman DI, et al. Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study. Circ Cardiovasc Genet 2009; 2: 134-141.
35. Phillips CM, Goumidi L, Bertrais S, et al. Additive effect of polymorphisms in the IL-6, LTA, and TNF-{alpha} genes and plasma fatty acid level modulate risk for the metabolic syndrome and its components. J Clin Endocrinol Metab 2010; 95: 1386-1394.
36. Morange PE, Tregouet DA, Godefroy T, et al. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. J Mol Med (Berl) 2008; 86: 1153-1161.
37. Gonzalez-Enriquez GV, Rubio-Benitez MI, Garcia-Gallegos V, Portilla-de Buen E, Troyo-Sanroman R, Leal-Cortes CA,. Contribution of TNF-308A and CCL2-2518A to carotid intima-media thickness in obese mexican children and adolescents. Arch Med Res 2008; 39: 753-759.
38. Hou L, Huang J, Lu X, Wang L, Fan Z, Gu D,. Polymorphisms of tumor necrosis factor alpha gene and coronary heart disease in a Chinese Han population: interaction with cigarette smoking. Thromb Res 2009; 123: 822-826.
39. Bis JC, Heckbert SR, Smith NL, et al. Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis 2008; 198: 166-173. (Pubitemid 351406372)
40. Enquobahrie DA, Smith NL, Bis JC, et al. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am J Cardiol 2008; 101: 1683-1688.
41. Garbaraviciene J, Diehl S, Varwig D, et al. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Exp Dermatol 2010; 19: 736-741.
42. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276. (Pubitemid 46095954)
43. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-330. (Pubitemid 352009830)
44. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-1796.
45. Meijer K, de Vries M, Al-Lahham S, et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS One 2011; 6: e17154.
46. Puig L,. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007-1011.
47. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-1251. (Pubitemid 350115673)
48. Boehncke WH, Boehncke S, Tobin AM, Kirby B,. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-307.
49. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG,. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-703.
50. Kimball AB, Guerin A, Latremouille-Viau D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 2010; 123: 350-357.
51. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-157.
52. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606. (Pubitemid 44436647)
53. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566. (Pubitemid 351239154)
54. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115. (Pubitemid 350298146)
55. Brauchli YB, Jick SS, Miret M, Meier CR,. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009; 160: 1048-1056.
56. Stern RS,. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol 2010; 130: 917-919.
57. Stern RS, Huibregtse A,. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol 2011; 131: 1159-1166.
58. Wakkee M, Herings RM, Nijsten T,. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-967.
59. Gelfand JM, Azfar RS, Mehta NN,. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol 2010; 130: 919-922.
60. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
61. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
62. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G,. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
63. Boehncke WH, Boehncke S, Schon MP,. Managing comorbid disease in patients with psoriasis. BMJ 2010; 340: b5666.
64. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-1042.
65. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862-872.
66. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218. (Pubitemid 40995372)
67. Araujo EP, De Souza CT, Ueno M, et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 2007; 148: 5991-5997. (Pubitemid 350146162)
68. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS,. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
69. Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011; 25: 1187-1193.
70. Bongartz T, Kudva Y,. Can treatment of chronic inflammatory diseases reduce the risk of diabetes mellitus? JAMA 2011; 305: 2573-2574.
71. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S,. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-2531.
72. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864-871.
73. Wu JJ,. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on the Risk of Myocardial Infarction in Patients with Psoriasis. American Academy of Dermatology, New Orleans, 2011.
74. Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol 2011; 12: 51-62.
75. Warnecke C, Manousaridis I, Herr R, et al. Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. Eu J Dermatol 2011; 21: 761-770.
76. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.